FDA Warns Faulty Glucometer Software Linked to One Death and 114 Injuries
A software flaw in True Metrix glucose meters causes dangerous misreadings. FDA urges diabetics to switch devices immediately.
Summary
The FDA has flagged a serious recall of True Metrix blood glucose monitoring systems made by Trividia Health, linked to one death and 114 serious injuries. A software bug causes the meter to display the same error code for two very different situations: dangerously high blood sugar and a faulty test strip. This confusion can lead patients to either ignore a life-threatening glucose spike or incorrectly treat themselves for high blood sugar when levels are actually normal or low. The FDA is urging healthcare providers to help patients transition to alternative glucose monitoring systems as soon as possible, while advising patients not to stop testing entirely until a replacement is in hand.
Detailed Summary
For people managing diabetes, accurate blood glucose readings are not a convenience — they are a lifeline. A newly elevated FDA safety warning highlights how a software flaw in a widely used glucose monitoring system has already contributed to one death and over 100 serious injuries, underscoring how critical device reliability is in daily diabetes management.
The core problem lies in Trividia Health's True Metrix blood glucose meters, which display an identical E-5 Error Code for two completely different situations: a blood glucose reading exceeding 600 mg/dL, and a test strip malfunction. This ambiguity creates a dangerous fork in patient decision-making. A person experiencing a genuine hyperglycemic crisis may assume the error is a strip defect and fail to seek urgent care. Conversely, someone with a faulty strip may believe they are dangerously hyperglycemic and administer unnecessary insulin, risking a hypoglycemic episode.
As of January 2026, the FDA had recorded one death and 114 serious injuries tied to this flaw. The agency classified the recall as Class I in February — its most serious designation — covering the True Metrix, True Metrix Air, True Metrix Go, and True Metrix Pro systems, along with co-branded store versions.
The FDA is urging healthcare providers to proactively contact affected patients and facilitate a transition to alternative glucose monitoring methods. High-risk patients — those on intensive insulin therapy, sulfonylureas, or those prone to frequent glucose swings — are prioritized for immediate transition. Critically, patients are advised not to stop monitoring altogether while awaiting a replacement device.
This is not an isolated incident in the glucose monitoring space. In 2025, Abbott issued a correction for sensors giving false low readings tied to hundreds of adverse events and seven deaths globally. These recurring issues highlight the need for patients and clinicians to stay vigilant about device recalls and maintain open communication with healthcare providers about monitoring equipment.
Key Findings
- True Metrix meters display the same E-5 error for dangerously high glucose and test strip faults, causing dangerous confusion.
- The recall is linked to one death and 114 serious injuries as of January 2026.
- FDA classified the recall as Class I — the most serious level — in February 2026.
- Patients on insulin or sulfonylureas are at highest risk and should prioritize switching devices immediately.
- Patients should not stop glucose testing entirely until an alternative monitoring method is available.
Methodology
This is a news report from MedPage Today summarizing an FDA safety communication and Class I recall notice. The source is a credible medical news outlet; the evidence basis is an official FDA advisory and reported adverse event data, not a peer-reviewed study.
Study Limitations
This article is a news summary of an FDA communication, not a primary research study, so detailed adverse event data has not been independently peer-reviewed. The total number of affected devices in circulation is not specified, limiting understanding of the recall's full scope. Patients should consult the FDA's official recall database and their healthcare provider for the most current guidance.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.